De novo design of generalizable allosteric modulators and peptide ligands for G protein coupled receptors
De novo design of generalizable allosteric modulators and peptide ligands for G protein coupled receptors
批准号:
10160902
负责人:
Christopher David Bahl
金额:
$17.98万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-07 至 2022-01-27
关键词:
AddressAffinityAgonistBindingBinding ProteinsBiologicalBiological AssayBrainC-terminalCell surfaceCommunitiesCustomDNADetergentsDiseaseDisulfidesDrug DesignDrug TargetingEngineeringEscherichia coliExtracellular DomainFDA approvedFamilyFluorescence-Activated Cell SortingG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsGeneticGoalsHeterotrimeric GTP-Binding ProteinsIndividualInvestigationLeadLigand BindingLigandsLuciferasesMediatingMethodsModelingMolecularMolecular ConformationN-terminalOligonucleotidesPeptidesPharmaceutical PreparationsProcessProductionProtein EngineeringProtein FamilyProtein SubunitsProteinsReceptor ActivationReporterResearchSignal TransductionSignaling ProteinSiteSourceSpecificityStructureSurfaceSynthetic GenesSystemTechnologyTestingTherapeuticTimeTransmembrane DomainWestern BlottingWorkYeastsbasedeep sequencingdesigndrug discoveryexperimental studyhigh throughput screeningimprovedin vivomimeticsnanobodiesoverexpressionpeptide structureprotein expressionprotein protein interactionprotein purificationprotein structurereceptorreceptor bindingreceptor functionscreeningsmall moleculestructural biologythermostabilitytool
中文摘要
项目总结
英文摘要
Project Summary
Roughly one third of all FDA approved drugs target G protein coupled receptors (GPCRs), and this protein
family holds myriad therapeutic opportunities yet to be discovered. GPCRs signal through allosteric changes in
protein structure, and there is a large unmet need for effective, highly generalizable tools for conformational
control of these receptors. This project has two Specific Aims, both of which employ computational protein
design with Rosetta to build proteins de novo that bind and modulate GPCR conformation. Upon ligand binding
and activation, GPCRs associate with and signal through G proteins. In the first Aim, we design proteins de
novo which mimic the interaction domain of the endogenous Gα protein subunit. Because the interaction
between receptor and Gα is highly conserved, the protein tools we propose to develop can be applied broadly.
Synthetic genes encoding de novo Gα mimetics have been expressed, and protein was purified from
Escherichia coli. Binding to several different detergent-solubilized GPCRs was demonstrated via pull-down and
Western blotting. Functional Gα mimetic proteins will be structurally characterized and used as templates for
re-engineering a small suite of mimetics for all Gα subtypes. Additionally, we propose to leverage the Gα
mimetics to enhance the expression and purification of GPCRs. To demonstrate this system, we will attempt to
produce three different GPCRs for the first time: super conserved receptor expressed in brain 1-3. In the
second aim, we will design disulfide constrained peptides to serve as agonists and antagonists for all
structure-enabled family B GPCRs. This receptor family recognizes endogenous peptide ligands, and they are
difficult to drug with small molecules. Structures that detail ligand recognition are available for 60% of family B
receptors; we will use these as the basis for de novo design of high-affinity antagonist ligands based on
disulfide-constrained peptides. We will then screen hundreds of thousands of rationally designed de novo
peptides using yeast display, fluorescence activated cell sorting, and deep sequencing. Our unique design
approach enables us to custom tailor the peptide topology so that we can readily convert our antagonists into
high affinity agonists by extending the peptide N-terminus. The efficacy of designed ligands identified via the
high-throughput screen will be assessed individually using a luciferase reporter assay for GPCR signaling. The
research proposed here represents the first time that computational de novo protein design will be applied to
control GPCR conformation. This work has the potential to create valuable tools to empower the GPCR
research community and accelerate discovery of lead therapeutics for many diseases.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.sbi.2020.10.015
发表时间:
2021-03
期刊:
Current opinion in structural biology
影响因子:
6.8
作者:
[Adolf-Bryfogle J, Teets FD, Bahl CD]
通讯作者:
Bahl CD
Complete Combinatorial Mutational Enumeration of a protein functional site enables sequence-landscape mapping and identifies highly-mutated variants that retain activity.
蛋白质功能位点的完整组合突变枚举可实现序列景观图谱并识别保留活性的高度突变变体。
DOI:
10.21203/rs.3.rs-2248327/v1
发表时间:
2023
期刊:
Research square
影响因子:
--
作者:
[Colom,MireiaSolà, Vucinic,Jelena, Adolf-Bryfogle,Jared, Bowman,JamesW, Verel,Sébastien, Moczygemba,Isabelle, Schiex,Thomas, Simoncini,David, Bahl,ChristopherD]
通讯作者:
Bahl,ChristopherD
Computational de novo design of a disulfide-rich miniprotein synthetic library and its application to engineer binders to neutralizing epitopes on Clostridium difficile toxins TcdA and TcdB
-
批准号:10318198
-
项目类别:
-
资助金额:$20.53万
-
财政年份:2020
-
负责人:Christopher David Bahl
-
依托单位:
海外基金